| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:HPK1-IN-9 CAS:2734168-78-4 Package:50mg/RMB 19420;25mg/RMB 14900;100mg/RMB 24625
|
Methanone, [3-(dimethylamino)-1-azetidinyl][4-[2-(1,2,3,4,4a,5-hexahydro-3-methylpyrazino[2,1-c][1,4]benzoxazin-8-yl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]phenyl]- manufacturers
- HPK1-IN-9
-
- $2785.00 / 50mg
-
2025-10-27
- CAS:2734168-78-4
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Methanone, [3-(dimethylamino)-1-azetidinyl][4-[2-(1,2,3,4,4a,5-hexahydro-3-methylpyrazino[2,1-c][1,4]benzoxazin-8-yl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]phenyl]- Basic information |
| Product Name: | Methanone, [3-(dimethylamino)-1-azetidinyl][4-[2-(1,2,3,4,4a,5-hexahydro-3-methylpyrazino[2,1-c][1,4]benzoxazin-8-yl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]phenyl]- | | Synonyms: | Methanone, [3-(dimethylamino)-1-azetidinyl][4-[2-(1,2,3,4,4a,5-hexahydro-3-methylpyrazino[2,1-c][1,4]benzoxazin-8-yl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]phenyl]-;HPK1-IN-9 | | CAS: | 2734168-78-4 | | MF: | C30H33N7O2 | | MW: | 523.63 | | EINECS: | | | Product Categories: | | | Mol File: | 2734168-78-4.mol | ![Methanone, [3-(dimethylamino)-1-azetidinyl][4-[2-(1,2,3,4,4a,5-hexahydro-3-methylpyrazino[2,1-c][1,4]benzoxazin-8-yl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]phenyl]- Structure](CAS/20210305/GIF/2734168-78-4.gif) |
| | Methanone, [3-(dimethylamino)-1-azetidinyl][4-[2-(1,2,3,4,4a,5-hexahydro-3-methylpyrazino[2,1-c][1,4]benzoxazin-8-yl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]phenyl]- Chemical Properties |
| density | 1.39±0.1 g/cm3(Predicted) | | pka | 10.62±0.50(Predicted) |
| | Methanone, [3-(dimethylamino)-1-azetidinyl][4-[2-(1,2,3,4,4a,5-hexahydro-3-methylpyrazino[2,1-c][1,4]benzoxazin-8-yl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]phenyl]- Usage And Synthesis |
| Uses | HPK1-IN-9 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-9 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 112) [1]. | | References | [1] Xie, Yuli, et al. Hpk1 inhibitor and preparation method and use thereof. Patent WO2021213317A1. |
| | Methanone, [3-(dimethylamino)-1-azetidinyl][4-[2-(1,2,3,4,4a,5-hexahydro-3-methylpyrazino[2,1-c][1,4]benzoxazin-8-yl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]phenyl]- Preparation Products And Raw materials |
|